Top 5 Misconceptions About Ketamine Therapy
Ketamine, an anesthetic commonly used in medical and veterinary settings, has been gaining traction as a therapy for treatment-resistant depression and other mental health issues. While the evidence of its effectiveness is growing, there are still many misconceptions about the safety and efficacy of ketamine therapy. This article will discuss the top five myths about ketamine therapy and help dispel any confusion or misunderstanding surrounding this promising treatment option.
Myth 1: Ketamine is Just a Party Drug
Ketamine is classified as a Schedule III drug in the U.S. and is only legally available with a prescription from a licensed healthcare provider. As such, it cannot be purchased over the counter or obtained through recreational use.
Since the 1960s, ketamine has had numerous use cases in the medical field, and recently it's shown promise as a novel treatment for many mental health conditions. Although ketamine can be abused recreationally, it should not be confused with other party drugs like MDMA or LSD.
Myth 2: Ketamine Therapy is Not Backed by Scientific Evidence
In reality, ketamine therapy is backed by many scientific studies that attest to its efficacy in treating treatment-resistant depression and other mental health disorders. Ketamine, especially its S-enantiomer, Esketamine, acts as an NMDA receptor antagonist and has been shown to provide rapid relief from depressive symptoms, often within hours of administration [1]. This feature distinguishes it from traditional antidepressants, which can take weeks to exert their effects. This relief has been observed to last from several days to weeks post-treatment and, when administered in a series, has shown promise in yielding enduring benefits.
Esketamine has received FDA approval in the form of a nasal spray called Spravato for treatment-resistant depression, further substantiating the clinical utility of ketamine in mental health care.
Myth 3: Ketamine Therapy is Not Safe
When administered by a qualified healthcare professional, ketamine therapy can be considered safe. However, there are certain risks associated with any medical procedure, including allergic reactions and cardiovascular complications. Therefore, patients should always speak to their doctor before treatment to ensure they know all potential risks.
Myth 4: Ketamine Therapy is Only for Severe Depression
Although ketamine has been found to be effective in treating severe depression, it can also help those with more moderate forms of depression and anxiety disorders such as post-traumatic stress disorder (PTSD) [2]. It has also been used successfully for chronic pain management [3]. Therefore, anyone seeking relief from their mental health symptoms may benefit from speaking to their doctor about these options.
Myth 5: Ketamine Therapy Is a Quick Fix and Doesn't Require Ongoing Treatment
While some patients do experience significant relief after just one session of ketamine therapy, most require several treatments spaced out over time in order to maintain the desired effects. Depending on the individual's needs and response to treatment, follow-up visits may be required every few weeks or months following the initial session. Therefore, ongoing care may be necessary to maintain the positive effects of your initial treatments.
In conclusion, while there are still many misconceptions surrounding ketamine therapy due to its association with recreational drug use, this promising new form of treatment offers hope for those suffering from various mental health issues. With proper guidance from a qualified healthcare professional and informed consent from the patient, ketamine therapy can prove beneficial in helping individuals find relief from their symptoms without relying solely on medications or psychotherapy.
At Psychly, we are committed to upholding the highest standards in our content creation process. We strive to ensure that all statements presented in our articles are supported by reliable, high-quality sources, such as peer-reviewed studies and reputable academic journals.
- The Psychly Team
- Moore, T. J., Alami, A., Alexander, G. C., & Mattison, D. R. (2022). Safety and effectiveness of NMDA receptor antagonists for depression: A multidisciplinary review. Pharmacotherapy, 42(7), 567–579. https://doi.org/10.1002/phar.2707
- Intensive 7-day Treatment for PTSD Combining Ketamine With Exposure Therapy (PTSD). (2023). Yale Medicine. https://www.yalemedicine.org/clinical-trials/combining-neurobiology-and-new-learning-ketamine-and-prolonged-exposure
- Orhurhu, V. J., Roberts, J. S., Ly, N., & Cohen, S. P. (2022, September 19). Ketamine in Acute and Chronic Pain Management. Nih.gov; StatPearls Publishing. https://www.ncbi.nlm.nih.gov/books/NBK539824/